Edge Therapeutics Inc (NASDAQ:EDGE) CEO Brian A. Leuthner sold 2,500 shares of the stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $9.92, for a total transaction of $24,800.00. Following the completion of the transaction, the chief executive officer now owns 95,236 shares of the company’s stock, valued at $944,741.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Edge Therapeutics Inc (NASDAQ EDGE) traded down $0.15 during trading on Wednesday, hitting $9.40. 98,901 shares of the stock traded hands, compared to its average volume of 62,955. The company has a quick ratio of 8.34, a current ratio of 8.34 and a debt-to-equity ratio of 0.20. Edge Therapeutics Inc has a twelve month low of $7.30 and a twelve month high of $13.50.

Edge Therapeutics (NASDAQ:EDGE) last posted its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.48) by $0.11. sell-side analysts anticipate that Edge Therapeutics Inc will post -1.7 EPS for the current fiscal year.

EDGE has been the subject of several recent analyst reports. Zacks Investment Research upgraded shares of Edge Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, August 29th. BidaskClub cut shares of Edge Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, August 14th.

Several institutional investors have recently bought and sold shares of the company. Schwab Charles Investment Management Inc. boosted its holdings in shares of Edge Therapeutics by 0.7% in the second quarter. Schwab Charles Investment Management Inc. now owns 75,279 shares of the biotechnology company’s stock valued at $773,000 after acquiring an additional 532 shares in the last quarter. Russell Investments Group Ltd. boosted its holdings in Edge Therapeutics by 16.9% during the second quarter. Russell Investments Group Ltd. now owns 11,959 shares of the biotechnology company’s stock worth $123,000 after buying an additional 1,733 shares in the last quarter. California State Teachers Retirement System boosted its holdings in Edge Therapeutics by 7.7% during the second quarter. California State Teachers Retirement System now owns 35,167 shares of the biotechnology company’s stock worth $361,000 after buying an additional 2,500 shares in the last quarter. Rhumbline Advisers boosted its holdings in Edge Therapeutics by 19.1% during the second quarter. Rhumbline Advisers now owns 19,960 shares of the biotechnology company’s stock worth $205,000 after buying an additional 3,195 shares in the last quarter. Finally, The Manufacturers Life Insurance Company boosted its holdings in Edge Therapeutics by 26.2% during the second quarter. The Manufacturers Life Insurance Company now owns 18,114 shares of the biotechnology company’s stock worth $186,000 after buying an additional 3,764 shares in the last quarter. Institutional investors and hedge funds own 50.26% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Edge Therapeutics Inc (EDGE) CEO Brian A. Leuthner Sells 2,500 Shares of Stock” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was stolen and reposted in violation of US & international trademark & copyright laws. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/12/06/edge-therapeutics-inc-edge-ceo-brian-a-leuthner-sells-2500-shares-of-stock.html.

About Edge Therapeutics

Edge Therapeutics, Inc is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company’s initial product candidates target rare, acute, life-threatening neurological and other conditions.

Insider Buying and Selling by Quarter for Edge Therapeutics (NASDAQ:EDGE)

Receive News & Stock Ratings for Edge Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edge Therapeutics Inc and related stocks with our FREE daily email newsletter.